参考文献/References:
[1] Dixon SJ,Lemberg KM,Lamprecht MR,et al. Ferroptosis:an iron-dependent form of nonapoptotic cell death[J]. Cell,2012,149(5):1060-1072.
[2] Stockwell BR,Friedmann Angeli JP,Bayir H,et al. Ferroptosis:a regulated cell death nexus linking metabolism,redox biology,and disease[J]. Cell,2017,171(2):273-285.
[3] Vanden Berghe T,Linkermann A,Jouan-Lanhouet S,et al. Regulated necrosis:the expanding network of non-apoptotic cell death pathways[J]. Nat Rev Mol Cell Biol,2014,15(2):135-147.
[4] Tang D,Chen X,Kang R,et al. Ferroptosis:molecular mechanisms and health implications[J]. Cell Res,2021,31(2):107-125.
[5] Nakamura T,Naguro I,Ichijo H. Iron homeostasis and iron-regulated ROS in cell death,senescence and human diseases[J]. Biochim Biophys Acta Gen Subj,2019,1863(9):1398-1409.
[6] Lei P,Bai T,Sun Y. Mechanisms of ferroptosis and relations with regulated cell death:a review[J]. Front Physiol,2019,10:139.
[7] Yu H,Yang C,Jian L,et al. Sulfasalazine-induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor[J]. Oncol Rep,2019,42(2):826-838.
[8] Magtanong L,Ko PJ,Dixon SJ. Emerging roles for lipids in non-apoptotic cell death[J]. Cell Death Differ,2016,23(7):1099-1109.
[9] Kagan VE,Mao G,Qu F,et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis[J]. Nat Chem Biol,2017,13(1):81-90.
[10]Golej DL,Askari B,Kramer F,et al. Long-chain acyl-CoA synthetase 4 modulates prostaglandin E?release from human arterial smooth muscle cells[J]. J Lipid Res,2011,52(4):782-793.
[11]Doll S,Proneth B,Tyurina YY,et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition[J]. Nat Chem Biol,2017,13(1):91-98.
[12]Feng H,Stockwell BR. Unsolved mysteries:how does lipid peroxidation cause ferroptosis?[J]. PLoS Biol,2018,16(5):e2006203.
[13]McDonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J,2021,42(36):3599-3726.
[14]Moe GW,Marín-García J.Role of cell death in the progression of heart failure[J]. Heart Fail Rev,2016,21(2):157-167.
[15]Murphy SP,Kakkar R,McCarthy CP,et al. Inflammation in heart failure:JACC state-of-the-art review[J]. J Am Coll Cardiol,2020,75(11):1324-1340.
[16]Stockwell BR,Jiang X,Gu W. Emerging mechanisms and disease relevance of ferroptosis[J]. Trends Cell Biol,2020,30(6):478-490.
[17]Tsurusaki S,Tsuchiya Y,Koumura T,et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis[J]. Cell Death Dis,2019,10(6):449.
[18]Wang C,Yuan W,Hu A,et al. Dexmedetomidine alleviated sepsis-induced myocardial ferroptosis and septic heart injury[J]. Mol Med Rep,2020,22(1):175-184.
[19]Fang X,Wang H,Han D,et al. Ferroptosis as a target for protection against cardiomyopathy[J]. Proc Natl Acad Sci U S A,2019,116(7):2672-2680.
[20]Fang X,Cai Z,Wang H,et al. Loss of cardiac ferritin H facilitates cardiomyopathy via Slc7a11-mediated ferroptosis[J]. Circ Res,2020,127(4):486-501.
[21]Wang J,Deng B,Liu Q,et al. Pyroptosis and ferroptosis induced by mixed lineage kinase 3(MLK3) signaling in cardiomyocytes are essential for myocardial fibrosis in response to pressure overload[J]. Cell Death Dis,2020,11(7):574.
[22]Yin Z,Ding G,Chen X,et al. Beclin1 haploinsufficiency rescues low ambient temperature-induced cardiac remodeling and contractile dysfunction through inhibition of ferroptosis and mitochondrial injury[J]. Metabolism,2020,113:154397.
[23]Nishizawa H,Matsumoto M,Shindo T,et al. Ferroptosis is controlled by the coordinated transcriptional regulation of glutathione and labile iron metabolism by the transcription factor BACH1[J]. J Biol Chem,2020,295(1):69-82.
[24]Baba Y,Higa JK,Shimada BK,et al. Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes[J]. Am J Physiol Heart Circ Physiol,2018,314(3):H659-H668.
[25]Li W,Feng G,Gauthier JM,et al. Ferroptotic cell death and TLR4/Trif signaling initiate neutrophil recruitment after heart transplantation[J]. J Clin Invest,2019,129(6):2293-2304.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(5):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(5):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(5):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(5):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(5):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[11]王文杰 杨嘉馨 丁耀东 王可馨 牛佳龙 葛海龙.铁死亡在心血管疾病中的研究进展[J].心血管病学进展,2023,(5):420.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.009]
WANG Wenjie,YANG Jiaxin,DING Yaodong,et al.Ferroptosis in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2023,(5):420.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.009]